Evidence map›Paper›PMID 41944372›Full record

ArticleJournal of extracellular vesicles2026

Cisplatin Promotes Immunosuppression in Ovarian Cancer by Enhancing miR-181a-5p-Enriched Extracellular Vesicles to Drive Regulatory T Cell Differentiation.

Liyan Zheng, Sijia Mu, Mingxue Liu, Panmin Lei, Jingchen Zhang, Yuting Dai, Chenxi He, Fengli Qu, Weihong Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liyan ZhengZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Sijia MuZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Mingxue LiuCollege of Chemistry and Chemical Engineering, Qufu Normal University, Qufu, Shandong, China.
Panmin LeiZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Jingchen ZhangZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Yuting DaiZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Chenxi HeZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Fengli QuZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.ORCID https://orcid.org/0009-0003-2248-8609
Weihong TanZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.

Funding

foundation of Hangzhou Institute of Medicine, CAS 2024ZZBS04 2024ZZBS08Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang Province 2024R01005National Natural Science Foundation of China Nos. U25A20561 22504154 22274141Pioneer Research and Development Program of Zhejiang 2023SDYXS0002 2025SDYXS0001Research Funds of Hangzhou Institute for Advanced Study, UCAS 2023HIAS-Y029Zhejiang Provincial Health Commission Research Foundation WKJ-ZJ-242
6 · The paper itself

Abstract

Although cisplatin (CDDP) is widely employed in combination immunotherapy, no CDDP-based regimen has shown a survival benefit when treating the ovarian cancers. This is mainly because the impact of CDDP on immunotherapy is not fully understood. A critical gap concerns how CDDP reshape the tumour microenvironment, especially through extracellular vesicles (EVs)-mediated communication. In this work, using human and murine ovarian cancer cells as a model, we demonstrate that CDDP boosts the secretion of EVs from cancer cells, while exerting no such effect on non-cancerous cells. These CDDP-induced tumour-derived EVs, in turn, drive the differentiation of CD4

Indexed as

CisplatinExtracellular VesiclesMicroRNAsOvarian NeoplasmsT-Lymphocytes, RegulatoryAnimalsAntineoplastic AgentsCell DifferentiationCell Line, TumorFemaleForkhead Transcription FactorsHumansImmune ToleranceImmunosuppression TherapyMiceSirtuin 1Antineoplastic AgentsCisplatinForkhead Transcription FactorsMicroRNAsMIrn181 microRNA, humanSirtuin 1cisplatinextracellular vesiclesmicroRNAsovarian cancer

Identifiers

PMID41944372
PMCPMC13054833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.